Sort Out Different DOAC Options for Special Populations

November 2026

Using direct oral anticoagulants (DOACs) isn’t as cut-and-dried in special populations...patients with kidney disease, obesity, etc.

Take comorbidities into account when collaborating with specialist colleagues to pick a DOAC for primary or secondary thromboprophylaxis.

Chronic kidney disease (CKD). Be aware that all DOACs are generally safe down to Stage 4 CKD (eGFR 15-30 mL/min). But stay alert for possible dose reductions (dabigatran 75 mg bid, edoxaban 30 mg daily, etc).

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote